Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis
about
Advances in the management of myelofibrosisMechanisms of fibrosis: therapeutic translation for fibrotic diseaseEXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.Practical management of patients with myelofibrosis receiving ruxolitinib.Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Normal and malignant megakaryopoiesis.Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsAssessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
P2860
Q27008072-A962D166-C902-4774-9644-3C608F03EAE6Q29620307-A52FD7F4-B7C1-45B0-958C-0F17BD8F4E28Q33397674-6944D960-8E0A-43C3-89F1-5A687E219988Q33410649-D87FEDCF-B86E-4086-99FA-A009BE8532F2Q33632062-F3CB605A-F923-403D-8D32-324934C9BEFDQ33797357-BD6734B4-A024-4463-96E7-FF5B0FBFB390Q34718163-F517A372-F2C4-4AEC-91A1-2FFDEE846738Q35028968-53443B69-8B65-487E-8A4D-8FDF170E0902Q36612537-06A1EB80-0EAA-4E73-8576-10E7E8129696Q36909019-8295EA49-FF58-4F8F-B844-9CD91967C4B5Q38031262-291E9426-51EF-4873-A107-DF6F7CF77BBAQ38065306-FB673A0F-5C47-4E1B-8728-6F296D9BD00CQ38187674-A4BB5649-0322-46E3-BC6F-A3B13DE0EAA1Q40679370-F0D52F8E-9B7B-4EBF-A5BD-16B95C43B67BQ42554019-D1347AC1-7D23-490A-B9E9-397AEC8AD0FF
P2860
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic potential of Janus ...... he management of myelofibrosis
@en
Therapeutic potential of Janus ...... e management of myelofibrosis.
@nl
type
label
Therapeutic potential of Janus ...... he management of myelofibrosis
@en
Therapeutic potential of Janus ...... e management of myelofibrosis.
@nl
prefLabel
Therapeutic potential of Janus ...... he management of myelofibrosis
@en
Therapeutic potential of Janus ...... e management of myelofibrosis.
@nl
P2860
P1476
Therapeutic potential of Janus ...... he management of myelofibrosis
@en
P2860
P304
P356
10.1158/1078-0432.CCR-09-2836
P407
P577
2010-03-09T00:00:00Z